As it is now recommended to treat patients either before or shortly after liver transplantation, FCH should rarely be observed after liver transplantation. If it does occur, diagnosis of FCH should be made according to established criteria. Treatment with DAAs results in rapid clinical improvement and high rates of SVR. Clinical trial data evaluating the efficacy of DAAs are limited, but available data are encouraging. [70,87] In the absence of prospective clinical trials, we recommend people with FCH be treated with regimens recommended for people after liver transplantation, according to whether liver disease is compensated or decompensated (Table 5 and Table 6).